{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:23:08Z","timestamp":1791361388281,"version":"4.3.1"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.critrevonc.2020.102886","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T02:39:46Z","timestamp":1580265586000},"page":"102886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Mechanisms of resistance to mTOR inhibitors"],"prefix":"10.1016","volume":"147","author":[{"given":"Luigi","family":"Formisano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-8952","authenticated-orcid":false,"given":"Fabiana","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Marciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.102886_bib0005","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy","author":"Abraham","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0010","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.immunol.14.1.483","article-title":"Immunopharmacology of rapamycin","author":"Abraham","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0015","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-019-1253-5","article-title":"Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia","author":"Alves","year":"2019","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio.117","article-title":"Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases","author":"Apsel","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaa3870","article-title":"Architecture of human mTOR complex 1","author":"Aylett","year":"2016","journal-title":"Science (80-)"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0030","doi-asserted-by":"crossref","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","author":"Ballou","year":"2008","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0035","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","author":"Barr","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2008.11.007","article-title":"The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma","author":"Baumann","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0045","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-10-1099","article-title":"Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin","author":"Bhagwat","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0050","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-15-1640-T","article-title":"Treatment of triple-negative breast cancer with TORC1\/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population","volume":"76","author":"Bhola","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0055","doi-asserted-by":"crossref","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","author":"Bjornsti","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0060","doi-asserted-by":"crossref","DOI":"10.1038\/msb.2009.19","article-title":"Systems-level interactions between insulin-EGF networks amplify mitogenic signaling","author":"Borisov","year":"2009","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer","author":"Bosch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0070","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a000620","article-title":"Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR\/PI3K inhibitors BEZ235\/everolimus","author":"Brannon","year":"2016","journal-title":"Mol Case Stud"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2012.10.023","article-title":"JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer","author":"Britschgi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2011.11.027","article-title":"Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study","author":"Calvo","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2013.04.011","article-title":"Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study","author":"Campone","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0100","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2008.490","article-title":"Rapamycin induces transactivation of the EGFR and increases cell survival","author":"Chaturvedi","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0105","doi-asserted-by":"crossref","DOI":"10.3816\/CGC.2007.n.020","article-title":"Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma","author":"Cho","year":"2007","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0115","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0120","article-title":"PTEN regulatory functions in tumor suppression and cell biology","author":"Chu","year":"2004","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0125","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-09-0763","article-title":"Dual inhibition of Akt\/mammalian target of rapamycin pathway by nanoparticle albumin-bound \u2013rapamycin and perifosine induces antitumor activity in multiple myeloma","author":"Cirstea","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0130","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/cancers11091318","article-title":"PTEN alterations as a potential mechanism for tumor cell escape from PD-1\/PD-L1 inhibition","volume":"11","author":"Cretella","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0135","doi-asserted-by":"crossref","DOI":"10.1159\/000440724","article-title":"Gly388Arg FGFR4 polymorphism is not predictive of everolimus efficacy in well-differentiated digestive neuroendocrine tumors","author":"Cros","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0140","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdh388","article-title":"Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase\/Akt pathway","author":"DeGraffenried","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI37539","article-title":"Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus","author":"Di Nicolantonio","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0150","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00735-09","article-title":"Characterization of rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1","author":"Dibble","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0155","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","author":"Dos","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0160","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1314124110","article-title":"PI3K regulates MEK\/ERK signaling in breast cancer via the Rac-GEF, P-Rex1","author":"Ebi","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0165","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004015","article-title":"AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve","author":"Er","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0170","doi-asserted-by":"crossref","DOI":"10.1038\/emboj.2008.120","article-title":"The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C","author":"Facchinetti","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0175","doi-asserted-by":"crossref","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","author":"Faivre","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2006.03.029","article-title":"A dual PI3 kinase\/mTOR inhibitor reveals emergent efficacy in glioma","author":"Fan","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0185","doi-asserted-by":"crossref","DOI":"10.1111\/cas.13427","article-title":"Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis","author":"Fazio","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","author":"Feldman","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0195","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.13987","article-title":"Dual inhibition of the PI3K\/AKT\/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications","author":"Fourneaux","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0200","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-1549","article-title":"Molecular pathways: HER3 targeted therapy","author":"Gala","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0205","doi-asserted-by":"crossref","DOI":"10.1042\/BJ20090489","article-title":"Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)","author":"Garc\u00eda-Mart\u00ednez","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0210","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.4963","article-title":"Point mutations of the mTOR-RHEB pathway in renal cell carcinoma","author":"Ghosh","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0215","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","author":"Gibbons","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0220","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-3110","article-title":"Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a phase i trial","author":"Gonzalez-Angulo","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0225","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-13-0929","article-title":"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity","author":"Grabiner","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(02)00833-4","article-title":"Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action","author":"Hara","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0240","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.200403069","article-title":"The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins","author":"Harrington","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0245","doi-asserted-by":"crossref","DOI":"10.1038\/sj.clpt.6100317","article-title":"Rapamycin: something old, something new, sometimes borrowed and now renewed","author":"Hartford","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0250","doi-asserted-by":"crossref","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0255","article-title":"Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor","author":"Hoang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0260","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M111.304626","article-title":"The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)\/ eukaryotic translation initiation factor 4E (eIF-4E)\/ RAF pathway and act","author":"Hoang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0265","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.60.1971","article-title":"Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2","author":"Hortobagyi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0270","article-title":"Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells","author":"Hosoi","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0275","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-09-1314","article-title":"Everolimus","author":"Houghton","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0280","article-title":"Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program","author":"Houghton","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0285","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M508361200","article-title":"mTOR\u00b7RICTOR is the Ser473 kinase for Akt\/protein kinase B in 3T3-L1 adipocytes","author":"Hresko","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0290","doi-asserted-by":"crossref","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","author":"Hsieh","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0295","doi-asserted-by":"crossref","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","author":"Hsu","year":"2011","journal-title":"Science (80-)"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0300","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","author":"Hudes","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0305","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","author":"Hurvitz","year":"2013","journal-title":"Breast Dis."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","author":"Hutson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0315","doi-asserted-by":"crossref","DOI":"10.1038\/emboj.2008.146","article-title":"Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling","author":"Ikenoue","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0320","doi-asserted-by":"crossref","DOI":"10.21873\/anticanres.13159","article-title":"Chloroquine enhances rapamycin-induced apoptosis in MG63 cells","author":"Ishibashi","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0325","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","author":"Janku","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2013.12.035","article-title":"Assessing PIK3CA and PTEN in early-phase trials with PI3K\/AKT\/mTOR inhibitors","author":"Janku","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0335","article-title":"The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line","author":"Josset","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0340","article-title":"mTORC1-activated S6K1 phosphorylates rictor on threonine 1135 and regulates mTORC2 signaling","author":"Julien","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2012.09.029","article-title":"MTOR complex 2 regulates proper turnover of insulin receptor Substrate-1 via the ubiquitin ligase subunit Fbw8","author":"Kim","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0350","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.25133","article-title":"Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer","author":"Kimura","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0355","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22655","article-title":"Acquired resistance to PI3K\/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis","author":"Koh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2012.03.017","article-title":"MTOR signaling in growth control and disease","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0365","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.21.12.3995-4004.2001","article-title":"HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression","author":"Laughner","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0370","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-07-0702","article-title":"Targeting protein translation in human non-small cell lung cancer via combined MEK and mammalian target of rapamycin suppression","author":"Legrier","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0375","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.110.167940","article-title":"WJD008, a dual phosphatidylinositol 3-kinase (PI3K)\/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant","author":"Li","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0380","article-title":"Activation of PI3K\/AKT and MAPK pathway through a PDGFR\u03b2-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0385","article-title":"Rapamycin: one drug, many effects","author":"Li","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ddstr.2009.12.001","article-title":"MTOR mediated anti-cancer drug discovery","author":"Liu","year":"2009","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0395","doi-asserted-by":"crossref","DOI":"10.2147\/OTT.S115309","article-title":"Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells","author":"Liu","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0400","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0405","article-title":"Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","author":"Mayer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0410","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-08-4285","article-title":"Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235","author":"McMillin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0415","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors","author":"Millis","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0420","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-017-0442-3","article-title":"Phase I trial of MEK 1\/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors","author":"Mita","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0425","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-3377","article-title":"MEK Inhibitor PD-0325901 overcomes resistance to PI3K\/mTOR inhibitor PF-5212384 and potentiates antitumor effects in human head and neck squamous cell carcinoma","author":"Mohan","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0430","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0435","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0440","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2017.25","article-title":"Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2-advanced breast cancer: results from BOLERO-2","author":"Moynahan","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2011.12.024","article-title":"Inhibition of PI3K\/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells","author":"Muranen","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0450","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020382","article-title":"Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism","author":"Nepstad","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0455","doi-asserted-by":"crossref","DOI":"10.1111\/j.1356-9597.2004.00727.x","article-title":"Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function","author":"Oshiro","year":"2004","journal-title":"Genes Cells"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0460","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2008.144","article-title":"PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML","author":"Park","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0465","doi-asserted-by":"crossref","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0470","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-018-4779-x","article-title":"Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer","author":"Petrossian","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0475","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormonereceptor- positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","author":"Piccart","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0480","doi-asserted-by":"crossref","DOI":"10.1080\/15287394.2012.690325","article-title":"Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines","author":"Pinto-Leite","year":"2012","journal-title":"J. Toxicol. Environ. Heal. - Part A Curr. Issues"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2018.09.005","article-title":"The role of endothelial colony forming cells in kidney cancer\u2019s pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: a speculative review","author":"Poletto","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0490","article-title":"An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/- mice","author":"Puc","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0495","article-title":"Induction of MEK\/ERK activity by AZD8055 confers acquired resistance in neuroblastoma","author":"qing","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0500","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.9484","article-title":"Everolimus induces Met inactivation by disrupting the FKBP12\/Met complex","author":"Raimondo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0505","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-06-4615","article-title":"Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases","author":"Raynaud","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0510","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-10-0792","article-title":"Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens","author":"Rivera","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0515","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","author":"Rizzieri","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0520","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0525","doi-asserted-by":"crossref","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0530","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2013.360","article-title":"Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer","author":"Rosa","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0535","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance","author":"Rozengurt","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0545","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2010.28","article-title":"Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer","author":"Sato","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0550","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-018-0322-4","article-title":"A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K\/MTOR inhibitor voxtalisib in patients with advanced solid tumours","author":"Schram","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0555","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","author":"Serra","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0560","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2010.626","article-title":"PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer","author":"Serra","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0565","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-12-2102","article-title":"The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy","author":"Serra","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0570","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-009-1094-6","article-title":"Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors","author":"Shida","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0575","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-14-0669","article-title":"Dual PI3K\/mTOR inhibitors induce rapid over-activation of the MEK\/ERK pathway in human pancreatic cancer cells through suppression of mTORC2","author":"Soares","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0580","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2012.1487","article-title":"Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models","author":"Squillace","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0585","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-07-6854","article-title":"An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer","author":"Stemke-Hale","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0590","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","author":"Tabernero","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0595","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0600","doi-asserted-by":"crossref","DOI":"10.1038\/nature02866","article-title":"Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity","author":"Um","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0605","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bcp.2019.05.014","article-title":"Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line","volume":"166","author":"Van Der Steen","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0610","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.12070","article-title":"Synergistic activity of everolimus and 5-aza-2\u2032-deoxycytidine in medullary thyroid carcinoma cell lines","author":"Vitale","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0615","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-1833","article-title":"PTEN expression, not mutation status in TSC1, TSC2, or mTOR, correlates with the outcome on everolimus in patients with renal cell carcinoma treated on the randomized RECORD-3 trial","author":"Voss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0620","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1403352","article-title":"Response and acquired resistance to everolimus in anaplastic thyroid cancer","author":"Wagle","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0625","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02243-3","article-title":"Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0630","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16029","article-title":"Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study","author":"Weeber","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0635","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2011.42","article-title":"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs","author":"Weigelt","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0640","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2011.339","article-title":"The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia","author":"Willems","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0645","doi-asserted-by":"crossref","DOI":"10.4161\/trla.28174","article-title":"Signaling crosstalk between the mTOR complexes","author":"Xie","year":"2014","journal-title":"Translation"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0650","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9207.1","article-title":"mTOR inhibitors in cancer therapy","author":"Xie","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0655","article-title":"Evaluation and clinical analyses of downstream targets of the akt inhibitor GDC-0068","author":"Yan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0660","article-title":"eIF4E\/4E-BP ratio predicts the efficacy of mTOR targeted therapies","author":"Yanagiya","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0665","article-title":"MTOR kinase structure, mechanism and regulation","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0670","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0675","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0680","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis","author":"Yardley","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2017.06.033","article-title":"Focal adhesion- and IGF1R-dependent survival and migratory pathways mediate tumor resistance to mTORC1\/2 inhibition","author":"Yoon","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2020.102886_bib0690","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M115.049783","article-title":"Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)\/extracellular signal-regulated Kinase (ERK) paracrine signaling axis in basal-like breast cancer","volume":"14","author":"Young","year":"2015","journal-title":"Mol. Cell Proteom."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0695","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-09-0299","article-title":"Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin","author":"Yu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102886_bib0700","doi-asserted-by":"crossref","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","author":"Yu","year":"2011","journal-title":"Science (80-)"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282030024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282030024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:32:27Z","timestamp":1760902347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282030024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":140,"alternative-id":["S104084282030024X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102886","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of resistance to mTOR inhibitors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102886"}}